MX2011003502A - Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. - Google Patents
Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.Info
- Publication number
- MX2011003502A MX2011003502A MX2011003502A MX2011003502A MX2011003502A MX 2011003502 A MX2011003502 A MX 2011003502A MX 2011003502 A MX2011003502 A MX 2011003502A MX 2011003502 A MX2011003502 A MX 2011003502A MX 2011003502 A MX2011003502 A MX 2011003502A
- Authority
- MX
- Mexico
- Prior art keywords
- single chain
- chain antibody
- bispecific single
- antibody molecule
- species
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una molécula de anticuerpo de cadena sencilla biespecífica que comprende un primer dominio de enlace capaz de ligar a un epítopo de cadena CD3 épsilon de humano y primate no chimpancé, caracterizado porque el epítopo es parte de una secuencia de aminoácidos comprendida en el grupo que consiste de SEQ ID NOs 2, 4, 6 y 8, y un segundo dominio de enlace capaz de ligar a antígeno de membrana específico de próstata (PSMA). La invención también proporciona ácidos nucleicos que codifican la molécula de anticuerpo de cadena sencilla biespecífica así como vectores y células hospederas y un proceso para su producción. La invención además se refiere a composiciones farmacéuticas que comprenden la molécula de anticuerpo de cadena sencilla biespecífica y usos médicos de la molécula de anticuerpo de cadena sencilla biespecífica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10185708P | 2008-10-01 | 2008-10-01 | |
PCT/EP2009/062793 WO2010037836A2 (en) | 2008-10-01 | 2009-10-01 | Cross-species-specific psmaxcd3 bispecific single chain antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011003502A true MX2011003502A (es) | 2011-09-01 |
Family
ID=42073956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011003502A MX2011003502A (es) | 2008-10-01 | 2009-10-01 | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. |
Country Status (27)
Country | Link |
---|---|
US (5) | US20110293619A1 (es) |
EP (3) | EP2356153B1 (es) |
JP (4) | JP6126782B2 (es) |
KR (1) | KR101820535B1 (es) |
CN (1) | CN102171248B (es) |
AU (1) | AU2009299792B2 (es) |
BR (1) | BRPI0919841A2 (es) |
CA (1) | CA2738565C (es) |
CY (1) | CY1118303T1 (es) |
DK (1) | DK2356153T3 (es) |
ES (1) | ES2588155T3 (es) |
HK (1) | HK1158669A1 (es) |
HR (1) | HRP20160684T1 (es) |
HU (1) | HUE030090T2 (es) |
IL (1) | IL212099A (es) |
ME (1) | ME02485B (es) |
MX (1) | MX2011003502A (es) |
NZ (1) | NZ591134A (es) |
PL (1) | PL2356153T3 (es) |
PT (1) | PT2356153T (es) |
RS (1) | RS54900B1 (es) |
RU (1) | RU2559531C2 (es) |
SG (1) | SG194398A1 (es) |
SI (1) | SI2356153T1 (es) |
SM (1) | SMT201600256B (es) |
WO (1) | WO2010037836A2 (es) |
ZA (1) | ZA201101067B (es) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4059964A1 (en) * | 2007-04-03 | 2022-09-21 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
EP3375790A1 (en) * | 2008-10-01 | 2018-09-19 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
ME02485B (me) * | 2008-10-01 | 2017-02-20 | Amgen Res Munich Gmbh | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću |
EA201290020A1 (ru) | 2009-05-19 | 2013-10-30 | ЭйАйСи БЛЭБ КОМПАНИ | Композитный токоприемник и способы его изготовления |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
JP2014518615A (ja) * | 2011-04-22 | 2014-08-07 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 |
CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
CA2844540C (en) * | 2011-08-23 | 2018-10-16 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
EP2820047B1 (en) * | 2012-03-01 | 2018-04-25 | Amgen Research (Munich) GmbH | Long life polypeptide binding molecules |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
ES2676468T3 (es) | 2012-11-06 | 2018-07-19 | Bayer Pharma Aktiengesellschaft | Formulación de acopladores biespecíficos de linfocitos T (BiTE) |
CN103087171B (zh) * | 2012-12-24 | 2015-01-14 | 中国人民解放军第四军医大学 | 一种用于***癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法 |
CA3211863A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
EP2945969A1 (en) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP3620468A1 (en) | 2013-02-05 | 2020-03-11 | EngMab Sàrl | Method for the selection of antibodies against bcma |
EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
EP2970446A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Research (Munich) GmbH | Antibody constructs for influenza m2 and cd3 |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
WO2014143886A2 (en) * | 2013-03-15 | 2014-09-18 | Edimer Pharmaceuticals, Inc. | Anti-ectodysplasin antibodies |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US11634502B2 (en) | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
CA2918795A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
CA2895659A1 (en) | 2014-07-01 | 2016-01-01 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
ES2886523T3 (es) | 2014-11-26 | 2021-12-20 | Xencor Inc | Anticuerpos heterodiméricos que se unen a CD3 y CD20 |
AU2015353416C1 (en) | 2014-11-26 | 2022-01-27 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CD38 |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
CN114230667A (zh) | 2015-01-23 | 2022-03-25 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
CA2976360A1 (en) * | 2015-02-11 | 2016-08-18 | Aptevo Research And Development Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
CN114652827A (zh) | 2015-05-29 | 2022-06-24 | 安普希韦纳治疗公司 | 双特异性cd33和cd3结合蛋白质的使用方法 |
JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
ES2777602T3 (es) | 2015-08-03 | 2020-08-05 | Engmab Sàrl | Anticuerpos monoclonales contra el antígeno de maduración de células b humanas (BCMA) |
CN108350076B (zh) | 2015-08-17 | 2022-06-07 | 詹森药业有限公司 | 抗-bcma抗体,结合bcma和cd3的双特异性抗原结合分子及其用途 |
PE20181275A1 (es) | 2015-08-28 | 2018-08-03 | Amunix Operating Inc | Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo |
EA201890613A1 (ru) | 2015-09-21 | 2018-10-31 | Аптево Рисёрч Энд Девелопмент Ллс | Полипептиды, связывающие cd3 |
CN105198992B (zh) * | 2015-10-16 | 2018-07-13 | 中国人民解放军海军总医院 | 一种人源抗创伤弧菌溶血素蛋白(vvh)抗体的制备方法与应用 |
MX2018005545A (es) | 2015-11-02 | 2019-02-20 | Janssen Pharmaceutica Nv | Anticuerpos anti-il1rap, moleculas de union a antigenos biespecificas que se unen a il1rap y cd3, y usos de estas. |
US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
DK3411404T3 (da) * | 2016-02-03 | 2023-01-30 | Amgen Res Munich Gmbh | Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner |
US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
MX2018014228A (es) | 2016-05-20 | 2019-08-12 | Harpoon Therapeutics Inc | Proteina de union de albumina sérica de dominio unico. |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2017218707A2 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
MX2018016404A (es) | 2016-06-21 | 2019-10-15 | Teneobio Inc | Anticuerpos de union a cd3. |
WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
AU2017331256A1 (en) * | 2016-09-21 | 2019-04-04 | Aptevo Research And Development Llc | CD123 binding proteins and related compositions and methods |
EP3526241A1 (en) | 2016-10-14 | 2019-08-21 | Xencor, Inc. | Il15/il15r heterodimeric fc-fusion proteins |
CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
AU2017363300A1 (en) | 2016-11-23 | 2019-06-20 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
CN110520523A (zh) * | 2017-03-29 | 2019-11-29 | 台北医学大学 | 具抗原专一性的t细胞及其用途 |
US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
IL271194B1 (en) | 2017-06-20 | 2024-06-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
TWI728250B (zh) | 2017-06-21 | 2021-05-21 | 美商基利科學股份有限公司 | 靶向hiv gp120及cd3之多特異性抗體 |
CA3067603A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
HUE058233T2 (hu) | 2017-08-03 | 2022-07-28 | Amgen Inc | Interleukin-21-muteinek és kezelési eljárások |
US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
CA3078799A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10426424B2 (en) | 2017-11-21 | 2019-10-01 | General Electric Company | System and method for generating and performing imaging protocol simulations |
EP3728302A1 (en) | 2017-12-19 | 2020-10-28 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
EA202091557A1 (ru) | 2017-12-22 | 2020-11-18 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 |
UY38041A (es) | 2017-12-29 | 2019-06-28 | Amgen Inc | Construcción de anticuerpo biespecífico dirigida a muc17 y cd3 |
TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗pd-1抗體及治療方法 |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
CN112867734A (zh) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
SG11202011633SA (en) * | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Psma binding agents and uses thereof |
UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
EP3802599B1 (en) | 2018-06-03 | 2023-12-20 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
MX2021000783A (es) | 2018-07-31 | 2021-03-31 | Heidelberg Pharma Res Gmbh | Anticuerpos humanizados contra psma. |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Il-12ヘテロ二量体fc-融合タンパク質 |
CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
AU2020259405A1 (en) * | 2019-04-19 | 2021-09-23 | Janssen Biotech, Inc. | Methods of treating renal cancer with an anti- PSMA/CD3 antibody |
MX2021012767A (es) | 2019-04-19 | 2021-11-18 | Janssen Biotech Inc | Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3. |
PE20220575A1 (es) | 2019-06-14 | 2022-04-20 | Teneobio Inc | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 |
TWI809286B (zh) | 2019-07-05 | 2023-07-21 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
CN114786776A (zh) | 2019-09-18 | 2022-07-22 | 拉姆卡普生物阿尔法股份公司 | 针对ceacam5和cd3的双特异性抗体 |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
EP3842461A1 (en) | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
EP4090368A1 (en) | 2020-01-13 | 2022-11-23 | Aptevo Research and Development LLC | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
BR112022013725A2 (pt) | 2020-01-13 | 2022-10-11 | Aptevo Res & Development Llc | Formulações para agentes terapêuticos proteicos |
AU2021224851A1 (en) | 2020-02-21 | 2022-09-15 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
IL297601A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
WO2021228783A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceutica Nv | Methods for treating multiple myeloma |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
WO2022060878A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
EP4228694A1 (en) * | 2020-10-15 | 2023-08-23 | Janux Therapeutics, Inc. | Antibodies targeting psma and cd3 and uses thereof |
MX2023005322A (es) | 2020-11-06 | 2023-08-29 | Amgen Inc | Moleculas de union a antigeno biespecificas con multiples dianas de selectividad aumentada. |
EP4240770A1 (en) * | 2020-11-06 | 2023-09-13 | Amgen Research (Munich) GmbH | Polypeptide constructs selectively binding to cldn6 and cd3 |
MX2023006817A (es) | 2020-12-09 | 2023-08-14 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |
CR20230398A (es) | 2021-02-16 | 2023-11-15 | Janssen Pharmaceutica Nv | Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3 |
EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
CA3214594A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Trispecific antibody targeting cd79b, cd20, and cd3 |
WO2022232376A1 (en) | 2021-04-29 | 2022-11-03 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
MX2023012931A (es) | 2021-05-06 | 2023-11-13 | Amgen Res Munich Gmbh | Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas. |
JP2024519964A (ja) | 2021-05-21 | 2024-05-21 | アプティーボ リサーチ アンド デベロップメント エルエルシー | タンパク質治療薬のための投薬レジメン |
CN115536740A (zh) * | 2021-06-30 | 2022-12-30 | 苏州方德门达新药开发有限公司 | 介导细胞内有效滞留cd3的空间构象表位及其应用 |
WO2023183231A1 (en) | 2022-03-21 | 2023-09-28 | Amgen Inc. | Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer |
TW202346368A (zh) | 2022-05-12 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
EP0833907A1 (en) | 1995-06-23 | 1998-04-08 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
US20020142000A1 (en) * | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
SE524615C2 (sv) | 1999-06-30 | 2004-09-07 | Volvo Personvagnar Ab | Arrangemang för minskning av galvanisk korrosion mellan metallkomponenter |
KR100733933B1 (ko) * | 1999-07-29 | 2007-07-03 | 메다렉스, 인코포레이티드 | 전립선 특이적 막 항원에 대한 인간 모노클로날 항체 |
JP4386776B2 (ja) * | 2000-05-18 | 2009-12-16 | 日本たばこ産業株式会社 | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
RU2179862C1 (ru) * | 2000-12-26 | 2002-02-27 | Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" | Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки |
KR20040077889A (ko) * | 2002-01-28 | 2004-09-07 | 메다렉스, 인코포레이티드 | 전립선 특이적 막 항원 (psma)에 대한 인간모노클로날 항체 |
CA2515100A1 (en) * | 2003-02-06 | 2004-08-19 | Micromet Ag | Trimeric polypeptide construct to induce an enduring t cell response |
RU2005141512A (ru) * | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
US8784821B1 (en) * | 2003-05-31 | 2014-07-22 | Amgen Research (Munich) Gmbh | Human-anti-human cd3 binding molecules |
WO2005040220A1 (en) | 2003-10-16 | 2005-05-06 | Micromet Ag | Multispecific deimmunized cd3-binders |
US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
SI1716178T1 (sl) * | 2004-02-16 | 2010-11-30 | Micromet Ag | Manj imunogene vezne molekule |
SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
KR20070042967A (ko) * | 2004-07-16 | 2007-04-24 | 마이크로메트 에이지 | 발현 증강된 폴리펩티드 |
NO20064183L (no) | 2005-02-16 | 2006-11-08 | Micromet Ag | Mindre immunogene bindingsmolekyler |
CN101124249B (zh) * | 2005-02-18 | 2011-06-29 | 米德列斯公司 | 抗***特异性膜抗原(psma)的人单克隆抗体 |
EP1726650A1 (en) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
SG174779A1 (en) | 2005-09-12 | 2011-10-28 | Novimmune Sa | Anti-cd3 antibody formulations |
EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
ES2695047T3 (es) | 2007-04-03 | 2018-12-28 | Amgen Research (Munich) Gmbh | Dominio de unión específico entre especies |
EP4059964A1 (en) | 2007-04-03 | 2022-09-21 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
JP4970211B2 (ja) * | 2007-10-18 | 2012-07-04 | ヘキサゴン・メトロジー株式会社 | 3次元形状測定器 |
HRP20160857T4 (hr) * | 2008-10-01 | 2022-12-09 | Amgen Research (Munich) Gmbh | Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene |
ME02485B (me) * | 2008-10-01 | 2017-02-20 | Amgen Res Munich Gmbh | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću |
TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
DK3411404T3 (da) * | 2016-02-03 | 2023-01-30 | Amgen Res Munich Gmbh | Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner |
-
2009
- 2009-10-01 ME MEP-2016-156A patent/ME02485B/me unknown
- 2009-10-01 ES ES09783664.7T patent/ES2588155T3/es active Active
- 2009-10-01 EP EP09783664.7A patent/EP2356153B1/en active Active
- 2009-10-01 PT PT97836647T patent/PT2356153T/pt unknown
- 2009-10-01 EP EP22178586.8A patent/EP4180458A1/en not_active Withdrawn
- 2009-10-01 MX MX2011003502A patent/MX2011003502A/es active IP Right Grant
- 2009-10-01 JP JP2011529563A patent/JP6126782B2/ja active Active
- 2009-10-01 SI SI200931452A patent/SI2356153T1/sl unknown
- 2009-10-01 US US13/122,245 patent/US20110293619A1/en not_active Abandoned
- 2009-10-01 NZ NZ591134A patent/NZ591134A/xx unknown
- 2009-10-01 CA CA2738565A patent/CA2738565C/en active Active
- 2009-10-01 AU AU2009299792A patent/AU2009299792B2/en active Active
- 2009-10-01 RS RS20160506A patent/RS54900B1/sr unknown
- 2009-10-01 PL PL09783664.7T patent/PL2356153T3/pl unknown
- 2009-10-01 BR BRPI0919841-5A2A patent/BRPI0919841A2/pt not_active Application Discontinuation
- 2009-10-01 KR KR1020117009667A patent/KR101820535B1/ko active IP Right Grant
- 2009-10-01 DK DK09783664.7T patent/DK2356153T3/en active
- 2009-10-01 EP EP16167900.6A patent/EP3106468A1/en not_active Ceased
- 2009-10-01 CN CN200980138646.3A patent/CN102171248B/zh active Active
- 2009-10-01 HU HUE09783664A patent/HUE030090T2/en unknown
- 2009-10-01 SG SG2013073945A patent/SG194398A1/en unknown
- 2009-10-01 RU RU2011108687/10A patent/RU2559531C2/ru active
- 2009-10-01 WO PCT/EP2009/062793 patent/WO2010037836A2/en active Application Filing
-
2011
- 2011-02-10 ZA ZA2011/01067A patent/ZA201101067B/en unknown
- 2011-04-03 IL IL212099A patent/IL212099A/en active IP Right Grant
- 2011-12-07 HK HK11113216.8A patent/HK1158669A1/zh unknown
-
2015
- 2015-07-03 JP JP2015134815A patent/JP6643822B2/ja active Active
-
2016
- 2016-06-16 HR HRP20160684TT patent/HRP20160684T1/hr unknown
- 2016-08-02 SM SM201600256T patent/SMT201600256B/it unknown
- 2016-08-02 CY CY20161100757T patent/CY1118303T1/el unknown
-
2018
- 2018-06-27 US US16/020,558 patent/US20190169310A1/en not_active Abandoned
- 2018-07-05 JP JP2018128072A patent/JP2018198595A/ja active Pending
-
2021
- 2021-04-02 US US17/221,707 patent/US11472886B2/en active Active
- 2021-04-02 US US17/221,627 patent/US20230037742A1/en active Pending
- 2021-04-02 US US17/221,705 patent/US20210277143A1/en not_active Abandoned
- 2021-06-15 JP JP2021099390A patent/JP7273106B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011003502A (es) | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. | |
MX2012011405A (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
WO2010037838A3 (en) | Cross-species-specific single domain bispecific single chain antibody | |
MX2009010610A (es) | Dominio de enlace especifico de especies cruzadas. | |
WO2008119565A3 (en) | Cross-species-specific binding domain | |
MX348154B (es) | Anticuerpos de enlace a il-1-beta y fragmentos de los mismos. | |
MX2011003501A (es) | Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas. | |
MX2009010611A (es) | Enlazadores biespecificos, especificos para especies. | |
NZ597692A (en) | Anti-IGF antibodies | |
NZ717429A (en) | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly | |
WO2010037837A3 (en) | Bispecific single chain antibodies with specificity for high molecular weight target antigens | |
TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
UA110599C2 (uk) | Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку | |
NZ612512A (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
IL177337A0 (en) | Less immunogenic binding molecules | |
WO2009104074A3 (en) | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells | |
MX347295B (es) | Inmunoglobulinas portadoras y usos de las mismas. | |
EA201170980A1 (ru) | Пестицидные белки и способы их применения | |
MXPA04008077A (es) | Anticuerpos ant-a° y su uso. | |
EA201071323A1 (ru) | Axmi-115, axmi-113, axmi-005, axmi-163, axmi-184 инсектицидные белки и способы их применения | |
TN2012000138A1 (en) | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same | |
EP2292644A3 (en) | Small Streptococcus pyogenes antigens and their use | |
UA102061C2 (ru) | Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний | |
WO2010092176A3 (en) | Nontypable haemophilus influenzae antigens | |
JO2991B1 (ar) | بروتينات رابطة لمولد ضد المستقبل ايه للانترليوكين 17 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: BCN PEPTIDES, S.A.* |
|
FG | Grant or registration |